Objective: This study aims to determine the dose-dependent effects of testosterone on sexual function, body composition, muscle performance, and physical function in hysterectomized women with or without oophorectomy.
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Financial disclosure/conflicts of interest: S.B. has received research grant support from Abbott Pharmaceuticals and Eli Lilly and Co for investigator-initiated research unrelated to this study. S.B. has served as a consultant to Regeneron, Merck, and Eli Lilly and Co. No other potential conflict of interest relevant to this article was reported. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal_s Web site (www.menopause.org). T he clinical applications of testosterone for the treatment of sexual dysfunction, physical dysfunction, and osteoporosis in postmenopausal women are predicated on the assumption that testosterone dose-response relationships in women are different from those in men, and that clinically significant effects on health-related outcomes can be achieved safely at testosterone doses and concentrations that are substantially lower than those required to produce similar effects in men; however, these assumptions have not been tested rigorously. 1 Thus, an investigation of testosterone doseresponse relationships in women is needed to determine whether improvements in sexual function, muscle mass and performance, and physical function can be achieved at testosterone doses and concentrations that do not produce doselimiting androgenic adverse effects.
Despite the loss of estrogen production during natural menopause, the climacteric ovary continues to secrete a substantial amount of androgens 2 such that circulating testosterone levels change very little during the perimenopausal period. However, both hysterectomy and bilateral oophorectomy result in a substantial decline in testosterone levels. 3 Women who have undergone surgical oophorectomy experience greater deterioration in sexual function than naturally postmenopausal women despite estrogen therapy, 4<8 leading to speculation that surgically postmenopausal women with sexual dysfunction might benefit from testosterone replacement.
Several well-designed placebo-controlled trials using a transdermal testosterone patch have reported significant improvements in some domains of sexual function in both surgically and naturally postmenopausal women. 9<15 However, two phase III trials using a transdermal testosterone gel failed to meet the coYprimary endpoints of a greater increase in the total number of days with a satisfying sexual event and a greater increase in sexual desire when compared with placebo, but the study was underenrolled.
Very few studies have investigated the effects of testosterone administration on body composition, muscle performance, and physical function in women. Natural menopause is associated with an increase in fat mass and a decrease in lean body mass (LBM). 16, 17 The Study of Women's Health Across the Nation found higher rates of physical limitation in surgically postmenopausal women compared with naturally postmenopausal women. 18 Furthermore, the observed age-related decline in testosterone levels in older women has been associated with frailty. 19 Thus, surgically postmenopausal women with low testosterone levels may be at excess risk for physical disability. Clinical trials using various formulations and doses of testosterone or other androgens have reported some improvements in LBM and muscle strength 20<23 ; however, these results have not been consistent across studies, and none has demonstrated improvements in physical function. The dose-dependent effects of testosterone on skeletal muscle mass, measures of muscle performance, and physical function have not been studied.
Here, we evaluated the dose-response relationships of testosterone with several domains of sexual function and measures of body composition, muscle performance, and physical function in hysterectomized women with or without oophorectomy with low serum testosterone concentrations. The primary objective was to determine testosterone dose-dependent effects on a wide range of androgen-dependent outcomes in androgen-deficient women; thus, unlike other studies, we did not specifically recruit women with hypoactive sexual desire disorder or other forms of sexual dysfunction. We carefully monitored androgenic adverse effects using structured instruments: hair growth using the Ferriman-Gallwey scale, sebum production using Sebutape, acne using the Palatsi scale, and clitoral size using a caliper scale. We used intramuscular injections of graded doses of testosterone esters to achieve high levels of bioavailability and compliance, and a wide range of circulating testosterone concentrations, extending from physiologic to supraphysiologic range. Testosterone levels were measured using liquid chromatographyYtandem mass spectrometry, which is widely considered as the method with the highest sensitivity and specificity.
METHODS

Study design
The TDSM (Testosterone Dose Response in Surgically Menopausal Women) trial was a multicenter, parallel-group, placebo-controlled, double-blind, randomized trial consisting of a 12-week run-in period of transdermal estradiol administration, a 24-week treatment period, and a 16-week recovery period. The study was conducted at Boston University Medical Center (Boston, MA) and Charles Drew University of Medicine and Science (Los Angeles, CA) and was approved by the institutional review board at each study site. All participants provided written informed consent. Participant enrollment started in July 2005, and the last participant completed the trial on January 4, 2011. The trial was registered on June 28, 2007. An independent data and safety monitoring board reviewed study progress and safety data every 6 months.
Participants
Participants were healthy women aged 21 to 60 years who had undergone hysterectomy with or without partial or total oophorectomy. The participants had serum total testosterone concentrations less than 31 ng/dL or free testosterone concentrations less than 3.5 pg/mL (less than the median for healthy young women 24 ). Women who had undergone hysterectomy alone or partial oophorectomy were included if their follicle-stimulating hormone levels were 30 U/L or higher or if they were already receiving estrogen therapy. Inclusion required a documented normal Papanicolaou test and mammogram within the last 12 months.
Women with a major psychiatric illness (including newonset depression in the previous 3 mo or untreated depression), recent hospitalization, active cancers, poorly controlled diabetes mellitus (HbA1c 98.5%), uncontrolled hypertension, severe obesity (body mass index [BMI] 940 kg/m 2 ), illicit drug use, alcohol dependence, and abnormal liver function were excluded. Women who had been on a stable regimen of antidepressant therapy for 3 months or more were allowed to continue their antidepressant medications throughout the study. Women with a history of breast, ovarian, endometrial, or cervical cancer, hyperandrogenic disorders, physical disabilities, cardiac diseases, or thromboembolic disorders were excluded. Those taking glucocorticoids, androgens, spironolactone, and gonadotropin-releasing hormone agonists were also excluded.
Interventions and randomization
All eligible women were administered a regimen of transdermal estradiol patch applied twice a week and designed to achieve nominal delivery of 50 Kg of estradiol daily (Alora; Watson Pharmaceuticals) for a 12-week run-in phase. Women who were taking a different form of estrogen therapy before study entry were switched to the transdermal patch. This standardized estrogen patch regimen was used to minimize the confounding symptoms of low estrogen that may overlap with those of testosterone deficiency. After run-in, the participants were randomized to one of five groups to receive weekly intramuscular injections of placebo or 3, 6.25, 12.5, or 25 mg of testosterone enanthate (ENDO Pharmaceuticals, Malvern, PA) for 24 weeks. For blinding, all injections were preloaded into a syringe by the Investigational Drug Pharmacy and administered in the same volume by the research staff. A concealed computer-generated randomization table was used to allocate individuals to one of the five groups, with a block size of 6.
The trial was designed to obtain data on 128 women, assuming a 15% prior loss to follow-up. One hundred twentyeight evaluable participants would have yielded 90% power to detect differences across groups if the cumulative variation in the Brief Index of Sexual Functioning for Women (BISF-W) accounted for by randomized assignment (R 2 in a model including only randomized assignment) was 40%, but the study was underenrolled. With an a priori assumption that the SD of the BISF-W is 15, the enrollment actually achieved provides 80% power to detect a five-point increase in the BISF-W for each successive dose group.
Blinding
The investigators, study staff, and participants were blinded. The intervention assignment was known only to the Investigational Drug Pharmacy. All doses were prepared by the Investigational Drug Pharmacy in a similar volume of vehicle to maintain blinding.
Outcomes
The primary outcome was the change from baseline in composite and individual domain scores for sexual function, as measured by the BISF-W. The BISF-W was selected as our primary outcome because this instrument has been validated for the evaluation of sexual function in surgically postmenopausal women and has been shown to be androgen-responsive in pivotal trials. 9, 25 Sexual activity was assessed using a weekly Sexual Activity Log, and personal distress/bother associated with sexual dysfunction was assessed using the Female Sexual Distress Scale. To obtain a more comprehensive assessment of some domains that are not well covered by the BISF-W, we also used the Derogatis Interview for Sexual Functioning/Self-Report. Mood and well-being were assessed using the Psychological General Well-Being Index. 26<28 Additional secondary outcomes included changes in LBM, fat mass, maximal voluntary muscle strength, muscle power, and several performance-based measures of physical function.
Body composition was measured using dual-energy x-ray absorptiometry (QDR 4500A, Hologic, Bedford, MA) calibrated with a soft-tissue phantom. 29 Seated leg-press strength and chest-press strength were measured by the one repetition maximum (1RM) method 30 using pneumatic resistance machines (Keiser Sport, Fresno, CA). After a 5-minute warmup, loads were progressively increased until the participant was no longer able to complete a full range of motion repetition in good form. 1RM was defined as the greatest amount of resistance that could be successfully moved one time only. Grip strength was measured in both hands using an adjustable Jamar hydraulic dynamometer (Sammons Preston Inc, Bolingbrook, IL), as described elsewhere. 31 Muscle power, defined as the rate of exerting force, was determined at resistances equivalent to 50% to 70% of 1RM for leg press and chest press, using the equipment and software described for capturing strength. 32 Both tests were repeated within 7 days of the initial test; if the measurements were within 5%, the better of the two measures was recorded. Physical function was assessed using a 12-step stair-climb, a 40-m walk, and a liftand-lower task, as described previously. 33<35 The stair-climb and walk tests were performed with or without a load equal to 20% of the participant's body weight.
Blood counts, liver function tests, fasting glucose, lipids, presence of acne, hirsutism, sebum production, clitoral size, voice change, and adverse events were monitored. Sebum production was measured using Sebutapes applied to the forehead, nose, and back for 12 hours. 36 Hair growth was measured by the Ferriman-Gallwey scale, 37 and acne was measured using the Palatsi scale. 38 
Hormone assays
Serum total testosterone levels were measured by liquid chromatographyYtandem mass spectrometry with a sensitivity of 2 ng/dL, as described elsewhere. 39 The cross-reactivity of dehydroepiandrosterone, dehydroepiandrosterone sulfate, dihydrotestosterone, androstenedione, and estradiol in the testosterone assay was negligible at 10 times the circulating concentrations of these hormones. The interassay coefficient of variation was 15.8% at 12.0 ng/dL, 10.6% at 23.5 ng/dL, 7.9% at 48.6 ng/dL, 7.7% at 241 ng/dL, 4.4% at 532 ng/dL, and 3.3% at 1,016 ng/dL, respectively. As part of the Centers for Disease Control's Testosterone Assay Harmonization Initiative, quality control samples provided by the Centers for Disease Control were run every 3 months; bias in quality control samples in the range of 3.47 to 34.7 nmol/L (100-1,000 ng/dL) was less than 6.2%. Free testosterone was measured using equilibrium dialysis, with an interassay coefficient of variation of 12.3%. 24, 40 Sex hormoneYbinding globulin levels were measured using an immunofluorometric assay with a sensitivity of 0.5 nmol/L. 41 The interassay coefficients of variation were 8.3%, 7.9%, and 10.9%, and the intra-assay coefficients of variation were 7.3%, 7.1%, and 8.7%, respectively, in the low, moderate, and high pools.
Statistical analysis
All variables were examined using summary statistics. Compliance with treatment was assessed by the number of testosterone injections administered to the participant, expressed as percentage of the total number of doses intended by design. Percentage of compliance was averaged within each treatment group to obtain group means.
The primary analysis included all participants with a baseline measurement and at least one postrandomization measurement of the primary outcome. Mean change in outcomes was compared across treatment doses by linear regression, incorporating adjustment for baseline outcome measurements. Response at each dose was estimated using treatment contrast and 95% CI.
Missing data were addressed using multiple imputation by chained equations. 42 Treatment assignment, age, LBM, fat mass, and total testosterone levels were chosen as covariates for the imputation model providing estimates for missing values. Outcome questionnaires were imputed at the level of domains (subscores) such that partially complete records were retained and used. Ordinal variables were imputed using polytomous logistic regression, and continuous measures were imputed using a linear regression model. Fixed quantitative associations (for instance, relationships between domain scores and overall scores in the BISF-W) were maintained for the full course of the estimation of missing records through the use of passive imputation. 43 Twenty imputed values were generated for each record; this number was chosen to exceed 100 times the proportion of participant missing data in at least one domain of the primary outcome (12 of 62; 19.4%), typically an overestimate of the proportion of missing information for an outcome measure 44 and which greatly exceeded the total proportion of combined baseline and follow-up BISF-W questions missing in aggregate (9.9%). Each imputation was allowed to converge more than 25 iterations. Estimates of regression effects were computed by incorporating each of the imputed values, and the cumulative statistical significance of dose effects was determined using likelihood ratio statistics. 45 Comparisons of individual active doses to placebo used Wald statistics. Analyses of adverse event data were performed on observed data only.
Generalized additive models (GAMs) were used to evaluate the association between changes in each outcome measure and changes in total and free testosterone levels. 46 These models allow for curvilinearity in associations, if present, with preference for a simpler model if it is consistent with the data. GAMs were restricted to observed data. Analyses were conducted using R version 2.14.2 (R Foundation for Statistical Computing, Vienna, Austria). Multiple imputations were generated using the MICE library, 43 and GAM fits were derived using the mgcv package. 46 
RESULTS
Flow of participants through the study
Of the 850 women who underwent telephone screening, 218 met eligibility criteria: 85 entered the estrogen run-in period, 71 were randomized, and 62 had a baseline measurement and at least one postrandomization measurement, constituting the analytic sample for the primary analysis (placebo, n = 13; 3 mg, n = 12; 6.25 mg, n = 13; 12.5 mg, n = 13; 25 mg, n = 11; CONSORT diagram; Fig. 1 ).
Baseline characteristics
The treatment groups were similar in baseline characteristics ( Table 1 ). The mean age was 53 years, with a mean BMI of 29.8 kg/m 2 . Eighty percent of the women had undergone bilateral oophorectomy. The overall baseline sexual function scores of the study population were significantly lower than those observed previously in healthy women (Supplementary Table 1 , http://links.lww.com/MENO/A68). 25 
Compliance
The overall compliance with testosterone injections was 99% in the placebo group, 100% in the 3-mg group, 98% in the 6.25-mg group, 98% in the 12.5-mg group, and 98% in the 25-mg group.
Hormone levels
The baseline mean total and free testosterone concentrations of all randomized participants were 13.0 ng/dL and 2.2 pg/mL, respectively, well below the range for healthy menstruating women. Serum nadir total and free testosterone levels (measured on week 24, 1 wk after the previous injection) increased from baseline in a dose-dependent fashion (Fig. 2) . The mean ontreatment nadir total testosterone concentrations were 19, 78, 102, 128, and 210 ng/dL at the 0-, 3-, 6.25-, 12.5-, and 25-mg doses, respectively. On-treatment testosterone concentrations were significantly greater than levels reported in healthy cycling women. 47 
Sexual function
The changes in the composite scores for the BISF-W (the primary outcome of the trial) were significantly associated with testosterone dose and with the change from baseline in free testosterone concentrations (dose effect, P G 0.01; Fig. 3 ). The changes in sexual thoughts/desire and frequency of sexual activity were significantly greater in women assigned to the 25-mg group than in those assigned to the placebo group (P G 0.05 vs placebo). The changes in the other domains of sexual function (receptivity/initiation, relationship satisfaction, pleasure/orgasm, and problems affecting sexual function) were not related to on-treatment testosterone concentrations and did not differ from those in the placebo group ( Supplementary Fig. 1A , http://links.lww.com/MENO/A69). The changes in the domain scores for thoughts/desire, arousal, and frequency of sexual activity were also significantly related to increases in free testosterone concentrations (P G 0.05). The sexual activity scores measured by weekly logs showed a mean increase of 2.7 sexual encounters per week in the 25-mg group; the changes in sexual activity scores were significantly related to increases in free testosterone concentrations (P G 0.01; Fig. 3 ).
The scores on the Female Sexual Distress Scale (Fig. 3 ) and the Derogatis Interview for Sexual Functioning/Self-Report ( Supplementary Fig. 1A , http://links.lww.com/MENO/A69) did not significantly change when compared with placebo and were not related to on-treatment testosterone concentrations. The Psychological General Well-Being Index composite and vitality domain scores significantly increased in the 12.5-and 25-mg groups, respectively, when compared with placebo (P G 0.05 vs placebo; Fig. 3 ).
Body composition
Changes in LBM were significantly related to changes in free testosterone concentrations. The gains in LBM among women assigned to the 25-mg weekly dose averaged 1.8 kg and were significantly greater than those in the placebo group (P G 0.01; Fig. 4 ). The estimated between-person difference in LBM was 0.6 kg for each 100-ng/dL change in total testosterone concentrations (95% CI, 0.2-1.1; P = 0.003). There were no significant changes in total fat mass during intervention.
Muscle performance and physical function
Chest-press power and loaded stair-climb power significantly increased in the 25-mg group compared with placebo (mean increase in chest-press power, 27 W; P = 0.03; mean increase in loaded stair-climb power, 57 W; P = 0.03; Fig. 4 ). GAM indicated a significant relationship of changes in legpress strength, chest-press power, and loaded stair-climb power with changes in free testosterone concentrations after adjusting for baseline muscle function. Other performancebased measures of physical function (gait speed, lift-andreach, unloaded stair-climb speed or power) did not change significantly in any group and were not related to testosterone dose or on-treatment concentrations in these otherwise healthy women without any functional limitations ( Supplementary  Fig. 2 , http://links.lww.com/MENO/A69).
Results obtained from sensitivity analyses that controlled for baseline BMI did not meaningfully differ from those described above.
Hematocrit and metabolic parameters
Hemoglobin and hematocrit levels increased in a dosedependent fashion (Fig. 5) ; the increases in hemoglobin and hematocrit were significantly greater in women assigned to the 25-mg group than in those assigned to placebo (P G 0.05 vs placebo). Fasting glucose, lipid profile, and liver function tests did not significantly change from baseline and did not differ among groups.
Adverse events
The overall frequency of adverse events by physiologic system was similar among the treatment groups (Supplementary Table 2 , http://links.lww.com/MENO/A68). There were no serious or life-threatening testosterone-related adverse events. Clitoral size and Palatsi scale score did not differ among groups. There were small but significant increases in Ferriman-Gallwey scale score in the 12.5-and 25-mg groups when compared with placebo. Sebum production in the forehead, nose, and back did not change and did not differ significantly among groups (Fig. 6 ).
Nine women assigned to the testosterone arms reported acne; four of these nine women belonged to the 6.25-mg group. Three women (all in the 12.5-mg group) reported increased hair growth. Two women in the 25-mg group reported voice changes that were attributed to gastroesophageal reflux disease and resolved with proton-pump inhibitor therapy. There was no report of clitoromegaly. One woman in the 12.5-mg group reported increased libido as a negative complaint.
DISCUSSION
The concept of Bfemale androgen deficiency syndrome[ is predicated on the notion that a certain physiologic range of testosterone levels is necessary for the maintenance of androgendependent measures in women (eg, some aspects of sexual function, muscle mass and performance), that testosterone levels below this range are associated with an increased risk of impairment in these androgen-dependent measures (eg, sexual dysfunction), and that raising testosterone levels in women with low testosterone levels to the physiologic range would improve these androgen-dependent measures. 48, 49 Indeed, several well-designed randomized controlled trials in surgically postmenopausal women with hypoactive sexual desire have reported that administration of transdermal testosterone modestly improves some domains of sexual function such as sexual desire, satisfaction, and frequency. 9<13 However, two large phase III trials using a transdermal testosterone gel (Libi-Gel; Bio-Sante Inc) failed to show significant improvements in sexual function in women with hypoactive sexual desire disorder. In our dose-response study, in which we created a range of testosterone concentrations in oophorectomized and hysterectomized women, testosterone administration was associated with concentration-related improvements in some domains of sexual function (sexual thoughts/desires, sexual activity scores, and arousal), but not in other domains. Significant improvements were observed only at the highest dose of testosterone enanthate, which was associated with supraphysiologic on-treatment testosterone concentrations. In our trial of women not presenting with hypoactive sexual desire disorder or other forms of sexual dysfunction, physiologic testosterone doses resulted in no significant improvements.
Testosterone administration at supraphysiologic doses was associated with significant gains in LBM, chest-press power, and loaded stair-climb power. Miller et al 50 reported modest increases in LBM in women with hypopituitarism in response to testosterone administration. In the relatively healthy women without any physical dysfunction who participated in this trial, significant changes in other performance-based measures of physical function were not observed. Furthermore, significant improvements in LBM, chest-press power, and stair-climb power were observed only at the highest weekly dose of 25 mg, which was associated with nadir testosterone concentrations of 200 ng/dL (nearly five to six times the physiologic level); however, there were more consistent linear and nonlinear patterns of increases in LBM and muscle performance measures ( Fig. 4) when changes in these outcomes were modeled as a function of change in circulating free testosterone concentrations. These relationships were maintained even after adjusting for baseline BMI. Overall, the observed dose-response relationships of testosterone concentrations with changes in LBM, chest-press power, and stair-climb power render it improbable that significant gains in these outcomes could be achieved by raising testosterone levels to the physiologic range for healthy women. We did not find significant changes in fat mass within the 24-week administration of exogenous testosterone at any dose The results obtained from our population of women are consistent with the findings of other testosterone trials in human immunodeficiency virusYinfected women and women with hypopituitarism, 40<51 but are in contrast to those obtained from testosterone trials in men, in whom testosterone administration is associated with a significant loss of whole-body, subcutaneous, and visceral fat. Further research is needed to determine the mechanistic basis of this sex difference in the response of adipose tissue to testosterone administration. It is possible that testosterone doses larger than those used in this trial or a longer treatment duration may be necessary to achieve reductions in fat mass in women.
We observed few androgenic effects even at supraphysiologic doses, and there were no serious adverse events related to the intervention during the 6-month period of the study. Hemoglobin and hematocrit levels increased dose-dependently, but the changes were small, and both measures stayed within the reference range for women. Total cholesterol, low-density lipoprotein cholesterol, triglycerides, and fasting glucose did not change significantly. High-density lipoprotein cholesterol levels decreased with all testosterone dose groups in comparison with placebo, but the changes in high-density lipoprotein cholesterol were not significant. It is possible that concurrent estrogen therapy may have mitigated some of the androgenic adverse effects in our trial. The effects of testosterone therapy on cardiovascular and metabolic risks in women need further investigation in long-term, adequately powered trials 52 ; this dose-response study was not designed or powered to determine the long-term cardiovascular safety of testosterone in women. Long-term testosterone administration at doses that raise testosterone levels to five to six times the physiologic range may have adverse consequences on cardiovascular safety, either related to direct effects of testosterone or related to concurrent estrogen therapy.
Our study had notable strengths and some limitations. The trial had many features of a good trial design: concealed randomization, placebo control, blinding, and oversight by an independent data and safety monitoring board. The administration of testosterone by injection by the study staff ensured high rates of compliance and high levels of bioavailability. Furthermore, testosterone injections were effective in raising testosterone concentrations in a dose-dependent manner over a wide range. We measured total testosterone levels using liquid chromatographyYtandem mass spectrometry, which is widely considered as the reference method with the highest sensitivity and specificity. Free testosterone was measured using equilibrium dialysis method, which is also considered as a reference method. Sexual function was measured using the BISF-W, which has been validated in surgically postmenopausal women, and the findings of the BISF-W were corroborated using sexual activity logs. The sexual function domains that improved with testosterone administration (sexual thoughts/desire, sexual activity, arousal, and overall sexual activity scores) are consistent with previous reports. The sample size of this mechanistic dose-response study was guided by the primary aimVto detect significant relationships between testosterone concentrations and significant changes in measures of sexual function, muscle mass, and muscle performance. Our trial was limited by the FIG . 6 . Androgenic adverse events. The data represent absolute mean (SE) changes in data for each treatment group. *A significant difference between mean on-treatment change in dose group and placebo at a 0.05 level. The P value displayed here is an overall F test for the significance of dose level, obtained via analysis of covariance. small sample size attributed to low recruitment and large placebo effects that may have reduced the power to detect significant improvements, particularly in the lower-dose groups. We encountered a moderate proportion of missingness of data within the BISF-W that we addressed through imputation modeling. Although the BISF-W has been well-validated, this measure has a tendency toward a high noise-to-signal ratio, which may prevent detection of subtle effects. Our assessments of sexual function (and other outcomes) controlled for baseline to account for between-group variation at baseline. The women in our study were healthy, medically stable women who were not recruited for hypoactive sexual desire disorder or other forms of sexual dysfunction; it is possible that lower testosterone doses or concentrations would have been effective in improving sexual function in women with hypoactive sexual desire disorder. It is also possible that women with undiagnosed depression in our sample may have influenced our findings, as we did not actively screen for depression with a validated instrument. In addition, a minority of women in our sample were on antidepressant therapy (29%), which may have influenced their sexual function.
CONCLUSIONS
By creating a wide range of testosterone concentrations from the physiologic to highly supraphysiologic range, our study provides novel information about the range of testosterone doses associated with potential beneficial effects on a variety of androgen-dependent outcomes in women. Our findings demonstrate that improvements in some measures of sexual function, LBM, and some domains of muscle performance and physical function in hysterectomized women with or without oophorectomy are related to testosterone dose and increases in testosterone concentrations. Although significant gains are observed only in the highest-dose group, which is associated with supraphysiologic testosterone concentrations, few androgenic adverse effects are observed. Long-term randomized trials are needed to determine whether patient-important improvements in sexual and physical function can be achieved safely with testosterone doses that do not induce virilization or worsen cardiometabolic risk.
